1-3 of 3
Silvana de Castro Faria
Close
Sort by
Journal Articles

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Luis Fayad, MD, Jorge E Romaguera, MD, Larry W Kwak, MD, PhD, Sattva S. Neelapu, MD, Fredrick Hagemeister, MD, Barbara Pro, MD, Silvana de Castro Faria, MD, Yuan Ji, PhD, Donald Berry, Daniela Buglio, MD, PhD, L. Jeffrey Medeiros, MD
Journal: Blood
Blood (2011) 118 (21): 3718.
https://doi.org/10.1182/blood.V118.21.3718.3718
Published: 2011
Journal Articles

Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma.

Anas Younes, MD, Amanda R Copeland, MS, Jorge Romaguera, MD, Luis Fayad, MD, Michelle Fanale, M.D., Silvana de Castro Faria, MD, PhD, L. Jeffrey Medeiros, MD, Ph.D, S. Percy Ivy, MD
Journal: Blood
Blood (2009) 114 (22): 3744.
https://doi.org/10.1182/blood.V114.22.3744.3744
Published: 2009
Journal Articles

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Anas Younes, MD, Michelle Fanale, M.D., Peter McLaughlin, Amanda R Copeland, MS, Silvana de Castro Faria, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Huan J. Zhu, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 588.
https://doi.org/10.1182/blood.V114.22.588.588
Published: 2009